CAJ | 학술논문

目的：探讨人类错配修复蛋白1（MLH1）、错配修复蛋白2（MSH2）及细胞黏附分子变异体（CD44v6）在卵巢上皮性癌中的表达及临床意义。方法应用免疫组织化学 S-P 法检测 MLH1、MSH2及CD44v6在60例卵巢上皮性癌、35例卵巢交界性肿瘤和35例卵巢良性肿瘤组织中的表达。结果MLH1在卵巢上皮性癌和交界性肿瘤中的阳性表达率分别为43．33％（26／60）、48．57％（17／35），均明显低于于良性肿瘤阳性表达率的91．43％（32／35），差异有统计学意义（χ2＝20．16、15．31，均 P ＜0．05）。卵巢上皮性癌和交界性肿瘤 MSH2的阳性表达率分别为38．33％（23／60）、51．43％（18／35），均明显低于良性肿瘤阳性表达率的88．57％（31／35），差异有统计学意义（χ2＝22．74、11．49，均 P ＜0．05）。MLH1的表达率在卵巢上皮性癌有无淋巴结转移组、高级别与低级别组比较有差异，但差异无统计学意义（χ2＝2．24、1．19，均 P ＞0．05）。MSH2的表达下调与卵巢上皮性癌的分化程度、有无淋巴结转移及临床分期密切相关（χ2＝5．22、7．86、4．38，均 P ＜0.05）。CD44v6在卵巢上皮性癌、交界性肿瘤和良性肿瘤中阳性表达率分别为78．33％（47／60）、54．29％（19／35）、17．14％（6／35），差异有统计学意义（χ2＝33．55、10．52，均 P ＜0．05）。CD44v6与卵巢上皮性癌有无淋巴结转移及临床分期密切相关（χ2＝6．10、5．88，均 P ＜0．05）。结论MLH1、MSH2和 CD44v6在卵巢上皮性癌的发生、进展、侵袭中起到重要调控作用，并是判断其预后的重要参考指标。
목적：탐토인류착배수복단백1（MLH1）、착배수복단백2（MSH2）급세포점부분자변이체（CD44v6）재란소상피성암중적표체급림상의의。방법응용면역조직화학 S-P 법검측 MLH1、MSH2급CD44v6재60례란소상피성암、35례란소교계성종류화35례란소량성종류조직중적표체。결과MLH1재란소상피성암화교계성종류중적양성표체솔분별위43．33％（26／60）、48．57％（17／35），균명현저우우량성종류양성표체솔적91．43％（32／35），차이유통계학의의（χ2＝20．16、15．31，균 P ＜0．05）。란소상피성암화교계성종류 MSH2적양성표체솔분별위38．33％（23／60）、51．43％（18／35），균명현저우량성종류양성표체솔적88．57％（31／35），차이유통계학의의（χ2＝22．74、11．49，균 P ＜0．05）。MLH1적표체솔재란소상피성암유무림파결전이조、고급별여저급별조비교유차이，단차이무통계학의의（χ2＝2．24、1．19，균 P ＞0．05）。MSH2적표체하조여란소상피성암적분화정도、유무림파결전이급림상분기밀절상관（χ2＝5．22、7．86、4．38，균 P ＜0.05）。CD44v6재란소상피성암、교계성종류화량성종류중양성표체솔분별위78．33％（47／60）、54．29％（19／35）、17．14％（6／35），차이유통계학의의（χ2＝33．55、10．52，균 P ＜0．05）。CD44v6여란소상피성암유무림파결전이급림상분기밀절상관（χ2＝6．10、5．88，균 P ＜0．05）。결론MLH1、MSH2화 CD44v6재란소상피성암적발생、진전、침습중기도중요조공작용，병시판단기예후적중요삼고지표。
Objective To explore the expression and clinical significance of human mismatch repair protein1 (MLH1),mismatch repair protein2(MSH2)and cellular adhesion molecular variants(CD44v6)in ovarian epithelial carcinoma.Methods The immunohistochemical S -P method was used to detect the expression levels of MLH1, MSH2 and CD44v6 in 60 cases of ovarian epithelial carcinoma,35 cases of borderline ovarian tumor and 35 cases of ovarian benign tumor tissue.Results The positive expression rates of MLH1 in ovarian epithelial carcinoma and boundary tumor were 43.33%(26 /60),48.57%(17 /35),which were significantly lower than 91.43%(32 /35)of benign tumor (χ2 =20.16,15.31,all P <0.05).The positive expression rates of MSH2 in ovarian epithelial carcino-ma and boundary tumor were 38.33%(23 /60),51.43%(18 /35 ),which were significantly lower than 88.57%(31 /35)of benign tumor (χ2 =22.74,11.49,all P <0.05).MLH1 expression rate in ovarian epithelial carcinoma with or without lymph node metastasis group,high level and low level had differences,but the differences were not sta-tistically significant (χ2 =2.24,1.19,all P >0.05).The decreased expression of MSH2 was closely related to the differentiation degree of ovarian epithelial carcinoma,lymph node metastasis and clinical stage (χ2 =5.22,7.86, 4.38,all P <0.05).The positive expression rates of CD44v6 in ovarian epithelial carcinoma tumors,boundary tumors and benign tumors were 78.33%(47 /60),54.29%(19 /35),17.14%(6 /35),the differences were statistically sig-nificant (χ2 =33.55,10.52,all P <0.05).CD44v6 was closely related to lymph node metastasis of ovarian epithelial carcinoma and clinical stage (χ2 =6.10,5.88,all P <0.05).Conclusion MLH1,MSH2 and CD44v6 play impor-tant roles in the occurrence and development of ovarian epithelial carcinoma,and are important reference index to judge prognosis.